Details for Patent: 11,844,758
Which drugs does patent 11,844,758 protect, and when does it expire?
Patent 11,844,758 protects VORANIGO and is included in one NDA.
This patent has seventy-four patent family members in forty countries.
Summary for Patent: 11,844,758
| Title: | Therapeutically active compounds and their methods of use |
| Abstract: | Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein. |
| Inventor(s): | Zenon Konteatis, Janeta Popovici-Muller, Jeremy Travins, Robert Zahler, Zhenwei Cai, Ding Zhou |
| Assignee: | PHARMARESOURCES (SHANGHAI) CO Ltd , Servier Pharmaceuticals LLC |
| Application Number: | US17/158,867 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 11,844,758
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Servier | VORANIGO | vorasidenib | TABLET;ORAL | 218784-001 | Aug 6, 2024 | RX | Yes | No | 11,844,758 | ⤷ Start Trial | A METHOD OF TREATING A GLIOMA CHARACTERIZED BY AN IDHI MUTATION FOLLOWING SURGERY, WHEREIN THE GLIOMA IS GRADE 2 ASTROCYTOMA OR OLIGODENDROGLIOMA | ⤷ Start Trial | ||||
| Servier | VORANIGO | vorasidenib | TABLET;ORAL | 218784-002 | Aug 6, 2024 | RX | Yes | Yes | 11,844,758 | ⤷ Start Trial | A METHOD OF TREATING A GLIOMA CHARACTERIZED BY AN IDHI MUTATION FOLLOWING SURGERY, WHEREIN THE GLIOMA IS GRADE 2 ASTROCYTOMA OR OLIGODENDROGLIOMA | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,844,758
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3019483 | ⤷ Start Trial | C03019483/01 | Switzerland | ⤷ Start Trial |
| European Patent Office | 3019483 | ⤷ Start Trial | C20265008 | Finland | ⤷ Start Trial |
| European Patent Office | 3019483 | ⤷ Start Trial | 301370 | Netherlands | ⤷ Start Trial |
| European Patent Office | 3019483 | ⤷ Start Trial | CR 2026 00011 | Denmark | ⤷ Start Trial |
| European Patent Office | 3019483 | ⤷ Start Trial | PA2026510 | Lithuania | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
